Agennix raises $13M for late-stage cancer trial

Agennix has raised $13 million in a private placement with existing shareholders. This is the first step of a plan to refinance the company. "The funds we have raised will enable us to continue full-scale enrollment in the Phase III FORTIS-M trial in non-small cell lung cancer and to prepare for meetings with regulatory authorities to discuss the next steps following the positive Phase II trial of talactoferrin in severe sepsis," said CFO said Torsten Hombeck, Ph.D. Agennix release